CORE TEAM
Albert Wai-Kit CHAN, Ph.D., J.D.
Chairman
Dr. Albert Wai-Kit Chan is Partner at the Law Offices of Albert Wai-Kit Chan, PLLC. Dr. Chan handles all areas of intellectual property law (including technology transfer, patents, trademarks, copyrights, business transactions, and trade secrets), and his specialty is biotechnology patents. He is well-versed in all aspects of prosecution and litigation and is experienced in licensing, technology transfer and the evaluation of intellectual property portfolios.
From 1996 through 2013, Dr. Chan taught as an adjunct professor of law at The City University of New York School of Law. His classes included intellectual property law, patent law, technology transfer, Internet and the law, food and drug law, and international business law. He is currently adjunct associate professor in the School of Life Sciences at The Chinese University of Hong Kong and has adjunct professorship in the Department of Health Technology and Informatics at The Hong Kong Polytechnic University. Dr. Chan is active in a number of legal organizations including, among others, United States-China Intellectual Property Institute, Inc. (a New York Not-For-Profit Corporation) where he is founder and director.
Dr. Chan received his J.D. degree from Columbia University School of Law in New York. He was awarded his Ph.D. in virology at Baylor College of Medicine in Houston, Texas, and he completed his postdoctoral training at Cold Spring Harbor Laboratory in New York as an American Cancer Society postdoctoral fellow. Dr. Chan is registered to practice before the USPTO (1993) and has been admitted to practice in New Jersey (1992), New York (1993), Texas (2006), Massachusetts (2017) and the Supreme Court of the United States (2008).
Advisory Board
Keith K.H. Chan, Ph.D., FAAPS
Scientific Advisor
Former Director of FDA’s Office of Generic Drugs
Regulatory affairs and global strategy in drug development and commercialization
Dr. Keith Chan is a multifaceted professional with expertise in pharmaceutical science, regulation, academia, and entrepreneurship. He holds a Ph.D. in Pharmaceutics from the University of Minnesota and currently serves as the Senior Advisor of Cornerstone IP Foundation and Adjunct Professor at the Graduate Institute of Intellectual Property and Technology Management at National Chengchi University in Taiwan. Dr. Chan is also a Senior Partner at Bright Spot Management Consultants Corp, operating in China, Hong Kong, and Taiwan, and a Senior Research Fellow at the Institute of International Intellectual Property at Beijing University Law School. He holds various advisory roles for research institutes, regulatory agencies, and pharmaceutical companies in Asia and the United States.
With 15 years of experience at Ciba-Geigy Corporation (now Novartis), Dr. Chan has held senior and management positions. He has a remarkable publication record, with over 150 abstracts and research articles in peer-reviewed journals, as well as more than 200 professional presentations. In recognition of his scientific accomplishments in drug absorption, he was elected a fellow of the American Association of Pharmaceutical Scientists in 1995. Dr. Chan has also worked for the US FDA as Division Director at the Office of Generic Drugs. In 1997, he co-founded GloboMax LLC, a drug development organization, and later served as a consultant for pharmaceutical and biotech firms worldwide before the company was acquired by ICON, plc in 2003.
Over the past 15 years, Dr. Chan has played a vital role in assisting Asian companies, organizing workshops and conferences, and delivering lectures across China, Taiwan, Hong Kong, Singapore, and Korea. His aim has been to enhance the pharmaceutical industry in these regions through technology transfers, licensing, and new drug development projects. He has successfully guided several drug candidates from the investigational stage to market launch in various countries, including Japan, the United States, Asia, and Europe. Currently, Dr. Chan has embarked on a new venture, joining a professional strategy consulting firm to provide financial and investment networks to technology companies, thereby strengthening their financial structure and facilitating product development and market expansion.